🧵 Presented at #ESMO26:
Among patients with low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan improved progression-free survival vs physician’s choice of chemotherapy. Benefit was observed in both chemotherapy-naive patients and the overall population, supporting trastuzumab rezetecan as a potential treatment option in this setting.
https://ja.ma/4BqxAW0
@myESMO
3140 浏览 · 7 赞 · 1 转发 · 4 回复
Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgPatient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.org- JAMA@JAMA_current
This article is also featured in @JAMAWomenHealth, a curated source of trusted clinical information that advances health care for women worldwide. 📣 JAMA+ Women's Health amplifies the best of the JAMA Network’s rich Women’s Health content, ensuring it is accessible to global audience across the health spectrum. 📪 Learn more and subscribe to the email newsletter: https://ja.ma/4Bs8JRI
- JAMA@JAMA_current
🔖 This trial is featured in JAMA+ Trials, a platform that highlights the implications and innovations of #ClinicalTrial research from across the JAMA Network to advance evidence-based #medicine and public #health. This October's Trial Theme of the Month focuses on extension studies in #ClinicalTrials, where long-term findings depend on how comparison groups are defined and how attrition and selection bias are handled. Read the latest editorial: https://ja.ma/4j8Jop4 📫 Learn more and subscribe to the email newsletter: https://ja.ma/4jOy4yD
- JAMA@JAMA_current
📊 Research Summary: In low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan showed benefit in hormone receptor–positive and hormone receptor–negative disease, with more frequent hematologic toxicity than chemotherapy. https://ja.ma/4BmgfNQ #ESMO26 @myESMO
- JAMA@JAMA_current
💬 Editorial by Maria Fernanda Mosele, MD, and Fabrice André, MD, PhD: In #BreastCancer with low erythroblastic oncogene B 2 (ERBB2) expression, trastuzumab rezetecan demonstrates clinically meaningful activity and adds to the growing class of ERBB2-directed antibody-drug conjugates. Its place in care remains uncertain because trastuzumab deruxtecan is already approved in a similar setting and no head-to-head comparison is available. https://ja.ma/4em9sd2 #ESMO26 @myESMO
来源：JAMA · x.com